Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Cash from Investing Activities (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Cash from Investing Activities for 16 consecutive years, with -$348000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Investing Activities rose 68.68% to -$348000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.7 million, a 10.78% increase, with the full-year FY2024 number at -$1.3 million, up 25.29% from a year prior.
  • Cash from Investing Activities was -$348000.0 for Q3 2025 at Harvard Bioscience, down from -$233000.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $458000.0 in Q2 2024 to a low of -$1.1 million in Q3 2024.
  • A 5-year average of -$386421.1 and a median of -$401000.0 in 2023 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: plummeted 351.49% in 2023, then surged 173.28% in 2024.
  • Harvard Bioscience's Cash from Investing Activities stood at -$358000.0 in 2021, then skyrocketed by 34.36% to -$235000.0 in 2022, then tumbled by 351.49% to -$1.1 million in 2023, then surged by 56.08% to -$466000.0 in 2024, then grew by 25.32% to -$348000.0 in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Cash from Investing Activities are -$348000.0 (Q3 2025), -$233000.0 (Q2 2025), and -$683000.0 (Q1 2025).